Propellon Therapeutics

About:

Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein.

Top Investors: Jed McCaleb, FACIT, Rami Essaid, Dan Schultz

Description:

Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and proper histone modification. The overexpression of WDR5 and resulting deregulation of epigenetic mechanisms are implicated in various cancers and correlated with poor patient survival. Established by FACIT, Propellon’s WDR5 inhibitor platform arises from discoveries, research and innovations originating from OICR.